Garrett M. Nash, MD, MPH, FACS, FASCRS


Vice Chair for Quality and Safety, Department of Surgery

Conditions Treated

Surgeon Garrett Nash
LocationA pin, used as a metaphor for the concept of location. Locations Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
Phone iconAn icon showing a telephone. New Patient Appointments Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
Phone iconAn icon showing a telephone. Phone Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

About Me

I am a surgeon with specialized training in cancers of the colon, rectum, anus, appendix, and peritoneum. The focuses of my practice include minimally invasive techniques for colorectal cancer (including laparoscopy, single-incision laparoscopy, and robotic surgery), avoiding colostomy while preserving bowel, bladder, and sexual function, and the management of peritoneal surface malignancies (including pseudomyxoma peritonei and mesothelioma).

My clinical research involves prospective clinical trials of new technology and surgical techniques for advanced colorectal, appendiceal, and peritoneal malignancies, as well as optimizing surgical margins and lymph node retrieval for colon and rectal cancers.  I am the primary investigator for the ICARuS Trial (Intraperitoneal Chemotherapy After cytoReductive Surgery). This is a randomized clinical trial investigating the benefit of intraperitoneal chemotherapy for metastatic appendiceal and colorectal cancer.  It will be the first-ever prospective trial with the primary goal of measuring the efficacy of intraperitoneal chemotherapy for appendix cancer worldwide and the first randomized trial of intraperitoneal chemotherapy for colorectal cancer in the United States.

I have authored papers on a variety of subjects including cytoreductive surgery, intraperitoneal chemotherapy, minimally invasive surgery, sphincter-sparing rectal surgery, mechanisms of tumor progression, and predictors of outcome following surgery.

I have raised over $75,000 to support cancer research at Memorial Sloan Kettering by completing eleven races for Fred’s Team —  NYC Half Marathons each year from 2010 through 2014 and  NYC Marathons in 2010, 2011, 2013, 2014, 2015, and 2017. This November, I will be running the NYC Marathon to raise money for cancer research at MSK.

If you wish to make a donation for cancer research or learn more about Fred’s Team, please visit this website: Garrett Nash on Fred’s Team.

  • Clinical Expertise: Gastrointestinal cancers: primary and recurrent colon, rectal, anal, small bowel, and appendix cancers; carcinoid/neuroendocrine tumors; peritoneal surface malignancies; pseudomyxoma peritonei; mesothelioma. Minimally invasive and robotic surgery for small bowel and colorectal tumors. Preservation of bowel, bladder, and sexual function in patients with rectal cancer or pelvic tumors. Intraperitoneal chemotherapy. Clinical trials in surgery.
  • Awards and Honors: Castle Connolly: New York Magazine Best Doctors (2017-2018); Castle Connolly: America's Top Doctors (2016-2018); Castle Connolly: America's Top Doctors for Cancer (2016-2018)
  • Languages Spoken: English
  • Education: MD, Columbia University
  • Residencies: Surgery - University of Massachusetts Medical School; Surgery - New York Presbyterian/Weill Cornell Medical College
  • Fellowships: Colon and Rectal Surgery – NewYork-Presbyterian/Columbia and Weill Cornell; Colorectal Oncology - Memorial Sloan Kettering Cancer Center
  • Board Certifications: Surgery; Colon and Rectal Surgery

See My Colleagues


Visit PubMed for a full listing of Garrett M. Nash’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicare and New York State Medicaid also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.